PDCD1 and metastatic melanoma: Clinical responses to anti-PD-1 immunotherapy were associated with high diversity and relative abundance of Ruminococcaceae bacteria in prospectively collected microbiome samples from patients with metastatic melanoma (271) and relative abundance of A. muciniphila in patients with NSCLC, renal cell carcinoma, or urothelial carcinoma (272).